Search bioRxiv⌕ Search

Biology subjects

Gamazon, E.

Publications and source records attributed to Gamazon, E..

7 recordsLinked to original sources

GeneMAP: A discovery platform for metabolic gene function

Organisms maintain metabolic homeostasis through the combined functions of small molecule transporters and enzymes. While many of the metabolic components have been well-established, a substantial number remains without identified physiological substrates. To bridge this gap, we have leveraged large-scale plasma metabolome genome-wide association studies (GWAS) to develop a multiomic Gene-Metabolite Associations Prediction (GeneMAP) discovery platform. GeneMAP can generate accurate predictions, even pinpointing genes that are distant from the variants implicated by GWAS. In particular, our work identified SLC25A48 as a genetic determinant of plasma choline levels. Mechanistically, SLC25A48 loss strongly impairs mitochondrial choline import and synthesis of its downstream metabolite, betaine. Rare variant testing and polygenic risk score analyses have elucidated choline-relevant phenomic consequences of SLC25A48 dysfunction. Altogether, our study proposes SLC25A48 as a mitochondrial choline transporter and provides a discovery platform for metabolic gene function.

genomics↗

Hypergraph factorisation for multi-tissue gene expression imputation

AO_SCPLOWBSTRACTC_SCPLOWIntegrating gene expression across scales and tissues is crucial for understanding the biological mechanisms that drive disease and characterise homeostasis. However, traditional multi-tissue integration methods cannot handle uncollected tissues or rely on genotype information, which is subject to privacy concerns and often unavailable. To address these challenges, we present HYFA (Hypergraph Factorisation), a novel method for joint imputation of multi-tissue and cell-type gene expression. HYFA imputes tissue-specific gene expression via a specialised graph neural network operating on a hypergraph of individuals, metagenes, and tissues. HYFA is genotype- agnostic, supports a variable number of collected tissues per individual, and imposes strong inductive biases to leverage the shared regulatory architecture of tissues. In performance comparison on data from the Genotype Tissue Expression project, HYFA achieves superior performance over existing transcriptome imputation methods, especially when multiple reference tissues are available. Through transfer learning on a paired single-nucleus RNA-seq (snRNA-seq) dataset, we further show that HYFA can accurately resolve cell-type signatures from bulk gene expression, highlighting the methods ability to leverage gene expression programs underlying cell-type identity, even in tissues that were never observed in the training set. Using Gene Set Enrichment Analysis, we find that the metagenes learned by HYFA capture information about known biological pathways. Notably, the HYFA-imputed dataset can be used to identify regulatory genetic variations (eQTLs), with substantial gains over the original incomplete dataset. Our framework can accelerate effective and scalable integration of tissue and cell-type gene expression biorepositories.

bioinformatics↗

A systematic analysis of genetically regulated differences in gene expression and the role of co-expression networks across 16 psychiatric disorders and substance use phenotypes

Genome-wide association studies (GWASs) have identified thousands of risk loci for many psychiatric and substance use phenotypes, however the biological consequences of these loci remain largely unknown. We performed a transcriptome-wide association study of 10 psychiatric disorders and 6 substance use phenotypes (collectively termed "mental health phenotypes") using expression quantitative trait loci data from 532 prefrontal cortex samples. We estimated the correlation due to predicted genetically regulated expression between pairs of mental health phenotypes, and compared the results with the genetic correlations. We identified 1,645 genes with at least one significant trait association, comprising 2,176 significant associations across the 16 mental health phenotypes of which 572 (26%) are novel. Overall, the transcriptomic correlations for phenotype pairs were significantly higher than the respective genetic correlations. For example, attention deficit hyperactivity disorder and autism spectrum disorder, both childhood developmental disorders, showed a much higher transcriptomic correlation (r=0.84) than genetic correlation (r=0.35). Finally, we tested the enrichment of phenotype-associated genes in gene co-expression networks built from prefrontal cortex. Phenotype-associated genes were enriched in multiple gene co-expression modules and the implicated modules contained genes involved in mRNA splicing and glutamatergic receptors, among others. Together, our results highlight the utility of gene expression data in the understanding of functional gene mechanisms underlying psychiatric disorders and substance use phenotypes.

bioinformatics↗

Gene Expression Imputation with Generative Adversarial Imputation Nets

A question of fundamental biological significance is to what extent the expression of a subset of genes can be used to recover the full transcriptome, with important implications for biological discovery and clinical application. To address this challenge, we present GAIN-GTEx, a method for gene expression imputation based on Generative Adversarial Imputation Networks. In order to increase the applicability of our approach, we leverage data from GTEx v8, a reference resource that has generated a comprehensive collection of transcriptomes from a diverse set of human tissues. We compare our model to several standard and state-of-the-art imputation methods and show that GAIN-GTEx is significantly superior in terms of predictive performance and runtime. Furthermore, our results indicate strong generalisation on RNA-Seq data from 3 cancer types across varying levels of missingness. Our work can facilitate a cost-effective integration of large-scale RNA biorepositories into genomic studies of disease, with high applicability across diverse tissue types.

bioinformatics↗

A Gene Co-expression Network-based Analysis of Multiple Brain Tissues Reveals Novel Genes and Molecular Pathways Underlying Major Depression

Major depression is a common and severe psychiatric disorder with a highly polygenic genetic architecture. Genome-wide association studies have successfully identified multiple independent genetic loci that harbour variants associated with major depression, but the exact causal genes and biological mechanisms are largely unknown. Tissue-specific network approaches may identify molecular mechanisms underlying major depression and provide a biological substrate for integrative analyses. We provide a framework for the identification of individual risk genes and gene co-expression networks using genome-wide association summary statistics and gene expression information across multiple human brain tissues and whole blood. We developed a novel gene-based method called eMAGMA that leverages multi-tissue eQTL information to identify 99 biologically plausible risk genes associated with major depression, of which 58 are novel. Among these novel associations is Complement Factor 4A (C4A), recently implicated in schizophrenia through its role in synaptic pruning during postnatal development. Major depression risk genes were enriched in gene co-expression modules in multiple brain tissues and the implicated gene modules contained genes involved in synaptic signalling, neuronal development, and cell transport pathways. Modules enriched with major depression signals were strongly preserved across brain tissues, but were weakly preserved in whole blood, highlighting the importance of using disease-relevant tissues in genetic studies of psychiatric traits. We identified tissue-specific genes and gene co-expression networks associated with major depression. Our novel analytical framework can be used to gain fundamental insights into the functioning of the nervous system in major depression and other brain-related traits.\n\nAuthor summaryAlthough genome-wide association studies have identified genetic risk variants associated with major depression, our understanding of the mechanisms through which they influence disease susceptibility remain largely unknown. Genetic risk variants are highly enriched in non-coding regions of the genome and affect gene expression. Genes are known to interact and regulate the activity of one another and form highly organized (co-expression) networks. Here, we generate tissue-specific gene co-expression networks, each containing groups of functionally related genes or \"modules\", to delineate interactions between genes and thereby facilitate the identification of gene processes in major depression. We developed and applied a novel research methodology (called \"eMagma\") which integrates genetic and transcriptomic information in a tissue-specific analysis and tests for their enrichment in gene co-expression modules. Using this novel approach, we identified gene modules in multiple tissues that are both enriched with major depression genetic association signals and biologically meaningful pathways. We also show gene modules are strongly preserved across brain regions, but not in whole blood, suggesting blood may not be a useful tissue surrogate for the genetic dissection of major depression. Our novel analytical framework provides fundamental insights into the functional genetics major depression and can be applied to other neuropsychiatric disorders.

genetics↗

Gene expression imputation across multiple brain regions reveals schizophrenia risk throughout development.

Transcriptomic imputation approaches offer an opportunity to test associations between disease and gene expression in otherwise inaccessible tissues, such as brain, by combining eQTL reference panels with large-scale genotype data. These genic associations could elucidate signals in complex GWAS loci and may disentangle the role of different tissues in disease development. Here, we use the largest eQTL reference panel for the dorso-lateral pre-frontal cortex (DLPFC), collected by the CommonMind Consortium, to create a set of gene expression predictors and demonstrate their utility. We applied these predictors to 40,299 schizophrenia cases and 65,264 matched controls, constituting the largest transcriptomic imputation study of schizophrenia to date. We also computed predicted gene expression levels for 12 additional brain regions, using publicly available predictor models from GTEx. We identified 413 genic associations across 13 brain regions. Stepwise conditioning across the genes and tissues identified 71 associated genes (67 outside the MHC), with the majority of associations found in the DLPFC, and of which 14/67 genes did not fall within previously genome-wide significant loci. We identified 36 significantly enriched pathways, including hexosaminidase-A deficiency, and multiple pathways associated with porphyric disorders. We investigated developmental expression patterns for all 67 non-MHC associated genes using BRAINSPAN, and identified groups of genes expressed specifically pre-natally or post-natally.

genetics↗

Transcriptomic Imputation of Bipolar Disorder and Bipolar subtypes reveals 29 novel associated genes

Bipolar disorder is a complex neuropsychiatric disorder presenting with episodic mood disturbances. In this study we use a transcriptomic imputation approach to identify novel genes and pathways associated with bipolar disorder, as well as three diagnostically and genetically distinct subtypes. Transcriptomic imputation approaches leverage well-curated and publicly available eQTL reference panels to create gene-expression prediction models, which may then be applied to \"impute\" genetically regulated gene expression (GREX) in large GWAS datasets. By testing for association between phenotype and GREX, rather than genotype, we hope to identify more biologically interpretable associations, and thus elucidate more of the genetic architecture of bipolar disorder.\n\nWe applied GREX prediction models for 13 brain regions (derived from CommonMind Consortium and GTEx eQTL reference panels) to 21,488 bipolar cases and 54,303 matched controls, constituting the largest transcriptomic imputation study of bipolar disorder (BPD) to date. Additionally, we analyzed three specific BPD subtypes, including 14,938 individuals with subtype 1 (BD-I), 3,543 individuals with subtype 2 (BD-II), and 1,500 individuals with schizoaffective subtype (SAB).\n\nWe identified 125 gene-tissue associations with BPD, of which 53 represent independent associations after FINEMAP analysis. 29/53 associations were novel; i.e., did not lie within 1Mb of a locus identified in the recent PGC-BD GWAS. We identified 37 independent BD-I gene-tissue associations (10 novel), 2 BD-II associations, and 2 SAB associations. Our BPD, BD-I and BD-II associations were significantly more likely to be differentially expressed in post-mortem brain tissue of BPD, BD-I and BD-II cases than we might expect by chance. Together with our pathway analysis, our results support long-standing hypotheses about bipolar disorder risk, including a role for oxidative stress and mitochondrial dysfunction, the post-synaptic density, and an enrichment of circadian rhythm and clock genes within our results.

genetics↗